MXPA01008729A - Agentes para administracion intravitrea para tratar o prevenir desordenes del ojo. - Google Patents

Agentes para administracion intravitrea para tratar o prevenir desordenes del ojo.

Info

Publication number
MXPA01008729A
MXPA01008729A MXPA01008729A MXPA01008729A MXPA01008729A MX PA01008729 A MXPA01008729 A MX PA01008729A MX PA01008729 A MXPA01008729 A MX PA01008729A MX PA01008729 A MXPA01008729 A MX PA01008729A MX PA01008729 A MXPA01008729 A MX PA01008729A
Authority
MX
Mexico
Prior art keywords
eye
urea
derivatives
treat
agents
Prior art date
Application number
MXPA01008729A
Other languages
English (en)
Inventor
David Castillejos
Original Assignee
Vitreo Retinal Technologies In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitreo Retinal Technologies In filed Critical Vitreo Retinal Technologies In
Publication of MXPA01008729A publication Critical patent/MXPA01008729A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Metodos y preparacion para tratar desordenes del ojo y/o provocar desconexion o desinsercion vitrea posterior. Se administran al ojo en cantidades terapeuticamente efectivas, preparaciones que contienen (a) urea, (b) derivados de urea (e.g. hidroxiurea, tiourea), (c) un agente anti-inflamatorio no esteroidal, (d) antimetabolitos, (e) guanina, guanitidina, guanidinio, timidina, timitadina, uradina, uracilo, cistina), acido urico, acetal salicilato de calcio, sulfato de amonio u otro compuesto capaz provocar disolucion no enzimatica de la membrana hialoide o (e) cualquiera de sus posibles combinaciones.
MXPA01008729A 1999-03-02 2000-03-02 Agentes para administracion intravitrea para tratar o prevenir desordenes del ojo. MXPA01008729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12250399P 1999-03-02 1999-03-02
PCT/US2000/005587 WO2000051620A1 (en) 1999-03-02 2000-03-02 Agents for intravitreal administration to treat or prevent disorders of the eye

Publications (1)

Publication Number Publication Date
MXPA01008729A true MXPA01008729A (es) 2003-06-24

Family

ID=22403079

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01008729A MXPA01008729A (es) 1999-03-02 2000-03-02 Agentes para administracion intravitrea para tratar o prevenir desordenes del ojo.

Country Status (16)

Country Link
EP (1) EP1165095B1 (es)
JP (2) JP2002538125A (es)
KR (1) KR20010108296A (es)
CN (2) CN1377272A (es)
AT (1) ATE396734T1 (es)
AU (2) AU780299B2 (es)
BG (1) BG105867A (es)
BR (1) BR0008674A (es)
CA (1) CA2366050C (es)
DE (1) DE60039043D1 (es)
ES (1) ES2307498T3 (es)
IL (2) IL145226A0 (es)
MX (1) MXPA01008729A (es)
NZ (1) NZ513836A (es)
RU (1) RU2286157C2 (es)
WO (1) WO2000051620A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977385B2 (en) 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
WO2003007798A2 (en) * 2001-07-20 2003-01-30 Iomed, Inc. Ophthalmic use of 5 fluorourcil
DE60219189T2 (de) * 2001-07-20 2008-01-03 Iomed, Inc., Salt Lake City Iontophoretische okularvorrichtung zur abgabe von medikamenten auf methotrexat-basis und deren verwendung zur behandlung von neoplastischen, angiogenen, fibroplastischen und/oder immunsuppressiven augenunregelmässigkeiten
WO2003068166A2 (en) * 2002-02-13 2003-08-21 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
WO2003077898A1 (en) * 2002-03-14 2003-09-25 Vitreo-Retinal Technologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
MXJL02000046A (es) * 2002-12-13 2004-06-24 Jimenez Bayardo Arturo Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas.
CN101385697B (zh) * 2008-10-30 2012-10-03 中国科学院上海药物研究所 氟比洛芬酯眼用纳米乳-原位凝胶制剂及其制备方法
RU2497498C2 (ru) * 2012-02-14 2013-11-10 Константин Николаевич Руссков Фармацевтическая композиция для профилактики пролиферативной клеточной реакции "митомицин-о"
AU2013201465B2 (en) * 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CN103393631B (zh) * 2013-08-22 2015-04-08 北京蓝丹医药科技有限公司 一种氟比洛芬酯药物组合物
WO2015138391A1 (en) * 2014-03-11 2015-09-17 Rhee Douglas J Methods of treating glaucoma using amp-activated protein kinase (ampk) activators
TWI705812B (zh) 2014-12-01 2020-10-01 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
WO2017021560A1 (fr) * 2015-08-06 2017-02-09 Centre Hospitalier National D'ophtalmologie Quinze-Vingts Utilisation d'hydroxycarbamide pour prevenir la non-perfusion retinienne
EP3426685A1 (en) 2016-03-10 2019-01-16 Oxurion NV Posterior ocular fibrosis inhibition by antagonizing placental growth factor
CN109922794B (zh) * 2016-08-18 2022-11-04 特洛伊.布雷莫 使用脂质体构建体将尿素递送至黄斑和视网膜的细胞
WO2018208826A1 (en) * 2017-05-08 2018-11-15 Meharry Medical College Hydroxyurea to enhance sperm cells
GB2573784B (en) * 2018-05-17 2020-10-07 Nova Bio Pharma Product Dev Ltd A stable aqueous hydroxycarbamide solution
CN108721327A (zh) * 2018-08-24 2018-11-02 苏州药明康德新药开发股份有限公司 实验动物视网膜色素变性试验模型的制备方法
EP3920986A4 (en) * 2019-02-08 2022-10-26 Ohio State Innovation Foundation ANTIOXIDANT-RELEASING VITREOUS SUBSTITUTES AND THEIR USES
JP2022146830A (ja) * 2021-03-22 2022-10-05 均 石井 網膜剥離治療薬。

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0244178A3 (en) * 1986-04-28 1989-02-08 Iolab, Inc Intraocular dosage compositions and method of use
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
DK174702B1 (da) * 1987-09-11 2003-09-29 Syntex Llc Konserveringssystem til ophthalmiske formuleringer
US5470881A (en) * 1993-09-09 1995-11-28 West Virginia University Research Corporation Urea ophthalmic ointment and solution
US5441984A (en) * 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives
EP0785780A1 (en) * 1994-10-10 1997-07-30 Novartis AG Ophthalmic and aural compositions containing diclofenac potassium
US5891084A (en) * 1994-12-27 1999-04-06 Lee; Vincent W. Multiple chamber catheter delivery system
US5554187A (en) * 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system

Also Published As

Publication number Publication date
AU3720100A (en) 2000-09-21
IL145226A0 (en) 2002-06-30
ATE396734T1 (de) 2008-06-15
EP1165095A1 (en) 2002-01-02
NZ513836A (en) 2004-01-30
WO2000051620A1 (en) 2000-09-08
BR0008674A (pt) 2002-02-13
CN1377272A (zh) 2002-10-30
CN101711737A (zh) 2010-05-26
AU780299B2 (en) 2005-03-17
ES2307498T3 (es) 2008-12-01
DE60039043D1 (de) 2008-07-10
EP1165095A4 (en) 2004-12-15
BG105867A (en) 2002-04-30
CA2366050A1 (en) 2000-09-08
JP5428101B2 (ja) 2014-02-26
JP2011088911A (ja) 2011-05-06
JP2002538125A (ja) 2002-11-12
CA2366050C (en) 2011-05-24
IL145226A (en) 2007-07-04
EP1165095B1 (en) 2008-05-28
RU2286157C2 (ru) 2006-10-27
KR20010108296A (ko) 2001-12-07
AU2005202579A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
IL145226A0 (en) Agents for intravitreal administration to treat or prevent disorders of the eye
Baba et al. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.
Matthes et al. Inhibition of HIV-associated reverse transcriptase by sugar-modified derivatives of thymidine 5′-triphosphate in comparison to cellular DNA polymerases α and β
Furman et al. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview.
Bruns Adenosine receptors
MY121839A (en) Antiviral purine derivatives
Karnofsky et al. Cellular effects of anticancer drugs
Cronstein The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism
AU4690989A (en) Antiviral cytosine and guanine derivatives
Hartmann et al. Enhanced in vitro inhibition of HIV-1 replication by 3′-fluoro-3′-deoxythymidine compared to several other nucleoside analogs
CA2445744A1 (en) Antiviral nucleoside derivatives
MY103760A (en) Therapeutic nucleosides
NZ522326A (en) Adenosine A2A receptor antagonists
ATE336492T1 (de) Methonocarbacycloalkylanaloga von nucleosiden
IL95141A0 (en) Pharmaceutical compositions containing a pyrimidine nucleoside or a salt thereof
Calabresi Current status of clinical investigations with 6-azauridine, 5-iodo-2′-deoxyuridine, and related derivatives
Descamps et al. Relative potencies of different anti-herpes agents in the topical treatment of cutaneous herpes simplex virus infection of athymic nude mice
Broder Pharmacodynamics of 2′, 3′-dideoxycytidine: an inhibitor of human immunodeficiency virus
Merigan Treatment of AIDS with combinations of antiretroviral agents
Elion The purine path to chemotherapy (Nobel Lecture)
WO2002069943A3 (de) Die verwendung von pyrimidinnukleosiden und/oder prodrugs davon zur bekämpfung von nebenwirkungen der &#39;haart&#39; (highly active anti-retroviral therapy) und von anderen antiviralen therapien
MY105855A (en) Therapeutic nucleotides.
Baba et al. Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro
NO881190L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 9-(beta-d-deoxyribofuranosyl)-mucleosider.
Mansuri et al. Antiviral agents

Legal Events

Date Code Title Description
FG Grant or registration